Research Terms
Biochemistry Proteins Cell Biology Microbiology Molecular Biology Parasitology Molecular Parasitology Neurosciences Medical Sciences Cardiomyopathies Infectious Diseases Bacterial and Fungal Diseases Nosocomial Infections Parkinsons Disease Parasitic Diseases Tropical Diseases
Industries
Seyfang, A.; Kavanaugh, M.P. & Landfear, S.M. (1997). Aspartate 19 and Glutamate 121 Are Critical for Transport Function of the myo-Inositol/H+ Symporter from Leishmania donovani. Journal of Biological Chemistry 272: 24210-24215.
Barrett, M.P.; Tetaud, E.; Seyfang, A.; Bringaud, F. & Baltz, T. (1998). Trypanosome Glucose Transporters. Molecular and Biochemical Parasitology 91: 195-205.
Vasudevan, G.; Carter, N.S.; Drew, M.A.; Beverley, S.M.; Sanchez, M.A.; Seyfang, A.; Ullman, B. & Landfear, S.M. (1998). Cloning of Leishmania Nucleoside Transporter Genes by Rescue of a Transport-Deficient Mutant. Proceedings of the National Academy of Sciences, USA 95: 9873-9878.
Seyfang, A. & Landfear, S.M. (1999). Substrate Depletion Upregulates Uptake of myo-Inositol, Glucose and Adenosine in Leishmania. Molecular and Biochemical Parasitology 104: 121-130.
Seyfang, A. & Landfear, S.M. (2000). Four Conserved Cytoplasmic Sequence Motifs Are Important for Transport Function of the Leishmania Inositol/H+ Symporter. Journal of Biological Chemistry 275: 5687-5693.
Jin, J.H. & Seyfang, A. (2003). High-affinity myo-Inositol Transport in Candida albicans: Substrate specificity and pharmacology. Microbiology 140: 3371-3381.
Ling, J.; Pi, W.; Yu, X.; Bengra, C.; Long, Q.; Jin, H.; Seyfang, A. & Tuan, D. (2003). The ERV-9 LTR enhancer is not blocked by the HS5 insulator and synthesizes through the HS5 site non-coding, long RNAs that regulate LTR enhancer function. Nucleic Acids Research 31: 4582-4596.
Seyfang, A. & Jin, J.H. (2004). Multiple site-directed mutagenesis of more than 10 sites simultaneously and in a single round. Analytical Biochemistry 324: 285-291.
Mongan, T.P.; Ganapasam, S.; Hobbs, S.B. & Seyfang, A. (2004). Substrate Specificity of the Leishmania donovani myo-Inositol Transporter: Critical Role of Inositol C-2, C-3 and C-5 Hydroxyl Groups. Molecular and Biochemical Parasitology 135: 133-141.
Lin, T.; Gao, L.; Seyfang, A. & Oliver, Jr., J.H. (2005). ‘Candidatus Borrelia texasensis’, from the American dog tick Dermacentor variabilis. International Journal of Systematic and Evolutionary Microbiology 55: 685-693.
Seyfang, A. (2005). “Method for Multiple Site-Directed Mutagenesis.” U.S. Patent No. 6,878,531; International Patent Application (PCT) No. WO 2005/054492.
Liu, L.; Okuka, M.; Bailey, S.M.; Munoz, P.; Li, C.; Wu, C.; Czerwiec, E.; Sandler, L.; Seyfang, A.; Blasco, M.A. & Keefe, D.L. (2007). Telomere Lengthening Early in Development. Nature Cell Biology 9: 1436-1441.
Xue, C.; Liu, T.; Chen, L.; Li, W.; Liu, I.; Kronstad, J.W.; Seyfang, A. & Heitman, J. (2010). Role of an Expanded Inositol Transporter Repertoire in Cryptococcus neoformans Sexual Reproduction and Virulence. mBio 1(1): e00084-10.
Groer, M.W.; Yolken, R.H.; Beckstead, J.W.; Fuchs, D.; Mohapatra, S.S.; Seyfang, A. & Postalache, T.T. (2011). Prenatal Depression and Anxiety in Toxoplasma gondii Positive Women. Am. J. Obstet. Gynecol. 204(5): 433.e1-7.
Seyfang, A., Nazian, S.J., Saporta, S., Doupnik, C.A., Johnson, W.E. & Stevenson, F.T. (2012). Assessment of an Adjusted vs. Fixed Pass Line for Student Performance in a Medical School Curriculum. Medical Science Educator 22(4S): 270-271.
Seyfang, A., Saporta, S. & Johnson, W.E. (2013). Effect of Pre-Medical Education on Student Performance in a First-Year Medical School Curriculum. Medical Science Educator 23(4S): 712.
Duffy, A.R.; Beckie, T.M.; Brenner, L.A.; Beckstead, J.W.; Seyfang, A.; Postalache, T.T. & Groer, M.W. (2015). Relationship between Toxoplasma gondii and Mood Disturbance in Women Veterans. Military Medicine 180(6): 621-625.
Seyfang, A.; Bellur, A.; Wells, D. & Doenges, M. (2016). “Methods of Treating NFA-1 Organism Infection Using Apocynin.” U.S. Patent No. 9,492,455.
Seyfang, A.; Bellur, A.; Wells, D. & Doenges, M. (2017). “Methods of Treating NFA-1 Organism Infection Using Allopurinol.” U.S. Patent No. 9,655,901.
Seyfang, A.; Locksmith, T.J., Bellur, A., Wells, D. & Doenges, M. (2018). “Methods of Treating Acanthamoeba Infection Using Apocynin.” U.S. Patent No. 10,058,517.
Seyfang, A.; Massengill, C.L. & Sievers, S.R. (2019). “Transfection Vector for Pathogenic Amoebae and Use Thereof.” U.S. Patent No. 10,273,487.
Duffy, A.R.; O’Connell, J.R.; Pavlovich, M.; Ryan, K.A.; Lowry, C.A.; Daue, M.; Raheja, U.K.; Brenner, L.A.; Markon, A.O.; Punzalan, C.M.; Dagdag, A.; Hill, D.E.; Pollin, T.I.; Seyfang, A.; Groer, M.W.; Mitchell, B.D. & Postolache, T.T. (2019). Toxoplasma gondii Serointensity and Seropositivity: Heritability and Household-Related Associations in the Old Order Amish. International Journal of Environmental Research & Public Health 16: 3732-3740.
Seyfang, A., Locksmith, T.J., Bellur, A., Wells, D. & Doenges, M. (2020). “Methods of Treating Acanthamoeba Infection Using Allopurinol.” U.S. Patent No. 10,668,027.
Sharma, N.S., Vestal, G., Wille, K., Patel, K.N., Cheng, F., Tipparaju, S., Tousif, S., Banday, M.M., Xu, X., Wilson, L., Viswam, S.N., Morrow, C., Hayes, Jr., D., Seyfang, A., Barnes, S., Deshane, J.S. & Gaggar, A. (2020). Differences in Airway Microbiome and Metabolome of Single Lung Transplant Recipients. Respiratory Research 21: 104 (1-12).
Lim, S.J.*; Seyfang, A.*; Dutra, S.; Kane, B. & Groer, M.W. (2020). Gene expression responses to Zika virus infection in peripheral blood mononuclear cells from pregnant and non-pregnant women. MicrobiologyOpen 9(12): e1134 (1-21). *shared co-first authorship
International Association of Medical Science Educators (IAMSE), Member; 2012 - present
Society for Neuroscience (SfN), Member; 2006 - present
American Association for the Advancement of Science (AAAS), Member; 2000 - present
American Society for Microbiology (ASM), Member; 2000 - present
American Society for Biochemistry and Molecular Biology (ASBMB), Member; 2000 - present
Swiss National Science Foundation (SNSF) grants review, Swiss National Science Foundation (SNSF) grant review programme; 2009 - 2009
American Heart Association, Study Section R2 (Immunology & Virology; Microbiology/Microbial Pathogenesis), American Heart Association, Study Section R2 (Immunology & Virology; Microbiology/Microbial Pathogenesis); 2008 - 2010
US Department of Veterans Affairs, Research & Development Program, US Department of Veterans Affairs, Research & Development Program; 2007 - 2007
Louisiana Board of Regents/National Science Foundation (NSF), Louisiana Board of Regents/National Science Foundation grants review program; 2005 - 2007
American Heart Association, Southern & Ohio Valley Study Section 4B, American Heart Association, Southern & Ohio Valley Study Section 4B (Cell Transport & Metabolism; Immunology & Microbiology); 2004 - 2007
USUHS (Uniformed Services University of the Health Sciences), USUHS (Uniformed Services University of the Health Sciences) Intramural Research Program; 2004 - 2004
The Wellcome Trust, London (Infection & Immunology study section), The Wellcome Trust, London (Infection & Immunology study section); 2004 - 2004
US Department of Agriculture (USDA-NRI), US Department of Agriculture (USDA-NRI) Competitive Grants Program, Animal Health & Well-Being Program; 2003 - 2003
“Glu187, Asp300 and Glu429 in Conserved Cytoplasmic Sequence Motifs are Important for Transport Function of the Leishmania Inositol-Proton Symporter.”; “Membrane Proteins in Health and Disease”; Canadian Society of Biochemistry and Molecular & Cellular Biology, Banff, Alberta, Canada. (Apr 2, 1998); 1998
“Structure-Function Analysis of a Model Proton Symporter: The Leishmania myo-Inositol/Proton Transporter, MIT.”; Department of Biochemistry & Molecular Biology, Medical College of Georgia, Augusta, GA. (Jan 25, 1999); 1999
“Substrate Depletion Upregulates myo-Inositol Transporter and Uptake of Glucose and Adenosine in Leishmania.”; “Pathogenic Protozoa: Molecules, Structures and Mechanisms”; Forum of the Centre for Molecular Biology Heidelberg, Germany. (Mar 30, 1999); 1999
“Leishmania myo-Inositol/H+ Transporter MIT as a Model Proton Symporter from Early Eukaryotes: Structure-Function Analysis, Pharmacology, Regulation and MIT Knockouts.”; “Membrane Transporters: New Perspectives in Drug Delivery and Drug Targeting”; International Research Conference, Ascona, Switzerland. (Aug 8, 1999); 1999
“Leishmania myo-Inositol/H+ Transporter as a Model Proton Symporter from Early Eukaryotes: Structure-Function Analysis, Pharmacology, Regulation and MIT Knockouts.”; Tenth Annual Molecular Parasitology/Vector Biology Symposium, Athens, GA. (May 10, 2000); 2000
“Transporters in Protozoan Parasites: Pharmacological Target and Model Transporters in Early Eukaryotes”; FASEB (Federation of the American Society for Experimental Biology) Summer Research Conference, Tucson, AZ. (Jul 22, 2001); 2001
“Substrate Recognition and Pharmacology of myo-Inositol Transport in Trypanosoma cruzi.”; “Membrane Transporters: From Identification to Drug Delivery”; PharmaConference, Interlaken, Switzerland. (Aug 5, 2001); 2001
“Membrane Transporters and Nutrient Salvage in Parasitic Protozoa.”; Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, GA. (Feb 26, 2003); 2003
“Calmodulin-dependent Regulation of myo-Inositol Transport in the Protozoan Leishmania donovani.“; “Transporters and Drugs”; PharmaConference, Pontresina/St.Moritz, Switzerland. (Aug 5, 2003); 2003
“A Story of Candida albicans and his other Sugar-Coated Buddy, Cryptococcus neoformans.”; Microbiology and Biodefense Conference, Medical College of Georgia, Augusta, GA. (May 7, 2004); 2004
“Multiple Site-Directed Mutagenesis of More Than 10 Sites Simultaneously.”; Georgia Life Sciences Summit 2004, Atlanta, GA. (Sep 24, 2004); 2004
“Myocarditis- Infections of the Heart.”; American Heart Association, Florida/Puerto Rico Affiliate Headquarters, St. Petersburg, FL. (Nov 8, 2005); 2005
“Calmodulin-dependent Regulation of myo-Inositol Transport in the Protozoan Leishmania donovani.”; 22nd Meeting of The German Society for Parasitology, Vienna, Austria. (Feb 24, 2006); 2006
“Pharmacological Significance of Inositol Metabolism: From Microbial Pathogens to the Human Brain.”; 1st Annual Molecular Medicine Research Symposium, Tampa, FL. (Jun 8, 2006); 2006
“Structure-Function Analysis and Regulation of Leishmania myo-Inositol Transporter MIT.”; 2nd Annual Molecular Medicine Research Symposium, Tampa, FL. (Jun 21, 2007); 2007
“Post-Transcriptional Regulation of the Leishmania myo-Inositol Transporter by Substrate Depletion.”; 23rd Meeting of The German Society for Parasitology, Hamburg, Germany. (Mar 6, 2008); 2008
“Protozoan Parasites as Risk Factors in Transplantation: Chagas’ Disease, Leishmaniasis, and Toxoplasmosis.”; LifeLink® HealthCare Institute, Tampa, FL. (Oct 1, 2008); 2008
“Protozoan Parasites as Risk Factor in Cardiac Transplantation Surgery: Chagas’ Disease and Toxoplasmosis.”; LifeLink® HealthCare Institute and TGH Cardiac Transplant Program, Tampa, FL. (Oct 23, 2008); 2008
“Chagas Disease and Leishmaniasis as Risk Factors in Blood Transfusion.”; Claro Scientific, Inc. and Florida Blood Services, St. Petersburg, FL. (Apr 15, 2009); 2009
“Leishmania myo-Inositol Transporter MIT: Drug Delivery and Novel Therapeutic Target.”; “Leishmania – Collaborative Research Opportunities in North Africa and the Middle East”; NIH/NIAID and Institut Pasteur de Tunis Conference, Tunis, Tunisia. (Jun 23, 2009); 2009
“Trypanosoma brucei myo-Inositol Transporter TcMIT: Drug Delivery and Novel Therapeutic Target.”; International Symposium on the Centennial of the Discovery of Chagas Disease, Rio de Janeiro, Brazil. (Jul 9, 2009); 2009
“Opportunistic Microbial Pathogens: Chagas Disease and Leishmaniasis as Risk Factors in Blood Transfusion.”; Hillsborough Community College, Tampa, FL. (Oct 5, 2010); 2010
“Candida albicans Cytochrome b5 Reductase as Novel Pharmaceutical Target.”; USF Signature Interdisciplinary Program in Allergy, Immunology & Infectious Diseases (SIPAIID) seminar series, Tampa, FL. (Nov 4, 2010); 2010
“Candida Cytochrome b5 Reductase as Novel Target for Rational Drug Design.”; USF Department of Chemistry colloquium, Tampa, FL. (Mar 29, 2011); 2011
“Biochemical and Pharmacological Characterization of Cytochrome b5 Reductase as Novel Therapeutic Target in Candida albicans.”; "Human Fungal Pathogens: Molecular Mechanisms of Host-Pathogen Interactions and Virulence"; Fourth FEBS Advanced Lecture Course on Human Fungal Pathogens: Molecular Mechanisms of Host-Pathogen Interactions and Virulence, Nice-La Colle sur Loup, France. (May 12, 2011); 2011
"Assessment of an Adjusted vs. Fixed Pass Line for Student Performance in a Medical School Curriculum"; International Association of Medical Science Educators (IAMSE) Annual Meeting, Portland, OR. (Jun 25, 2012); 2012
Morsani College of Medicine, MDC 7 University of South Florida 12901 Bruce B. Downs Blvd. Tampa, FL 33612